Optison (Perflutren)

Perflutren, the active ingredient in Optison, is a ultrasound contrast agent presented as a suspension for intravenous injection for diagnostic imaging use. It enhances echocardiographic visualization and is employed in cardiac imaging procedures. GNH USA supplies Optison as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Optison as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Optison is an ultrasound contrast agent used in cardiac imaging pathways to improve image quality.

- Echocardiography (left ventricular opacification): Improves end‑diastolic and end‑systolic border detection. - Myocardial perfusion imaging: Enhances detection of perfusion defects. - Stress echocardiography: Provides clearer delineation of wall motion during pharmacologic stress.

Optison may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Flushing: Transient warmth and reddening of the skin. - Headache: Mild to moderate headache occurring shortly after injection. - Nausea: Temporary feeling of queasiness. - Injection site discomfort: Minor pain or irritation at the IV site. - Hypotension: Slight drop in blood pressure post‑administration.

Serious or Rare Side Effects: - Anaphylactoid reaction: Severe allergic‑type response requiring immediate medical attention. - Acute respiratory distress: Sudden difficulty breathing. - Cardiac arrhythmia: Irregular heart rhythm occurring during or after the procedure. - Pulmonary hypertension exacerbation: Worsening of pre‑existing pulmonary pressure issues. - Severe hypotension: Marked drop in blood pressure leading to syncope.

Before using Optison, clinicians should assess patient suitability and monitor for reactions.

- Contraindication: Known hypersensitivity to perflutren or any component of the formulation. - Caution: Use with caution in patients with severe cardiopulmonary disease. - Monitoring: Observe vital signs during and after administration. - Pregnancy: Avoid use unless clearly indicated; safety not established. - Breastfeeding: Discontinue if adverse effects observed in infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optison has a limited interaction profile, but certain agents may influence its safety or efficacy.

Major Interactions (Avoid): - Vasodilators: May potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: May mask signs of hypotension. - Diuretics: May affect intravascular volume status. - Sedatives: May enhance dizziness or fainting risk. - ACE inhibitors: May contribute to blood pressure changes. - Contrast agents (iodinated): Concurrent use may increase overall contrast load.